Poor Glycemic Control and Abrupt Onset of Diabetes in HCV Patients Receiving direct-acting Antiviral Drugs: Case Series

Braira Wahid; Muhammad Wasim; Komal Saleem; Muhammad Waqar; null Sajjad; Khansa Wahid; Manzoor Hussain; Muhammad Idrees

doi:10.2217/fvl-2017-0147

Poor Glycemic Control and Abrupt Onset of Diabetes in HCV Patients Receiving direct-acting Antiviral Drugs: Case Series

Braira Wahid, Muhammad Wasim, Komal Saleem, Muhammad Waqar, Sajjad, Khansa Wahid, Manzoor Hussain, Muhammad Idrees

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Aim: Hepatitis C virus (HCV) impairs glucose metabolism and interferes with insulin-signaling pathways. About a third of HCV-infected patients develop Type 2 diabetes mellitus. Several evidences correlated direct-acting antiviral (DAA) based treatment of HCV infection with improved glycemic control.

Patients & methods: Disturbance in glucose metabolism of two different HCV patients receiving DAA drugs was noticed.

Results: We observed the first evidence of abrupt onset of diabetes and poor glycemic control in two different obese patients respectively, following successful treatment of HCV with sofosbuvir and ribavirin.

Conclusion: This case is an evidence of potential glucose intolerance in HCV patients receiving DAA drugs. It further suggests the need for regular screening of patient during DAA therapy for early detection of diabetes or poor glycemic control.

Original language	English
Pages (from-to)	525-528
Number of pages	4
Journal	Future Virology
Volume	13
Issue number	8
DOIs	https://doi.org/10.2217/fvl-2017-0147
Publication status	Published - 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

DAA
diabetes
interferon
sofosbuvir

Access to Document

10.2217/fvl-2017-0147Licence: In Copyright

Cite this

@article{b9d624ebc5ca4b9b9e18d3dbc15a05e9,

title = "Poor Glycemic Control and Abrupt Onset of Diabetes in HCV Patients Receiving direct-acting Antiviral Drugs: Case Series",

abstract = "Aim: Hepatitis C virus (HCV) impairs glucose metabolism and interferes with insulin-signaling pathways. About a third of HCV-infected patients develop Type 2 diabetes mellitus. Several evidences correlated direct-acting antiviral (DAA) based treatment of HCV infection with improved glycemic control. Patients & methods: Disturbance in glucose metabolism of two different HCV patients receiving DAA drugs was noticed. Results: We observed the first evidence of abrupt onset of diabetes and poor glycemic control in two different obese patients respectively, following successful treatment of HCV with sofosbuvir and ribavirin. Conclusion: This case is an evidence of potential glucose intolerance in HCV patients receiving DAA drugs. It further suggests the need for regular screening of patient during DAA therapy for early detection of diabetes or poor glycemic control.",

keywords = "DAA, diabetes, interferon, sofosbuvir",

author = "Braira Wahid and Muhammad Wasim and Komal Saleem and Muhammad Waqar and Sajjad and Khansa Wahid and Manzoor Hussain and Muhammad Idrees",

year = "2018",

doi = "10.2217/fvl-2017-0147",

language = "English",

volume = "13",

pages = "525--528",

journal = "Future Virology",

issn = "1746-0794",

publisher = "Taylor & Francis",

number = "8",

}

TY - JOUR

T1 - Poor Glycemic Control and Abrupt Onset of Diabetes in HCV Patients Receiving direct-acting Antiviral Drugs

T2 - Case Series

AU - Wahid, Braira

AU - Wasim, Muhammad

AU - Saleem, Komal

AU - Waqar, Muhammad

AU - Sajjad, null

AU - Wahid, Khansa

AU - Hussain, Manzoor

AU - Idrees, Muhammad

PY - 2018

Y1 - 2018

N2 - Aim: Hepatitis C virus (HCV) impairs glucose metabolism and interferes with insulin-signaling pathways. About a third of HCV-infected patients develop Type 2 diabetes mellitus. Several evidences correlated direct-acting antiviral (DAA) based treatment of HCV infection with improved glycemic control. Patients & methods: Disturbance in glucose metabolism of two different HCV patients receiving DAA drugs was noticed. Results: We observed the first evidence of abrupt onset of diabetes and poor glycemic control in two different obese patients respectively, following successful treatment of HCV with sofosbuvir and ribavirin. Conclusion: This case is an evidence of potential glucose intolerance in HCV patients receiving DAA drugs. It further suggests the need for regular screening of patient during DAA therapy for early detection of diabetes or poor glycemic control.

AB - Aim: Hepatitis C virus (HCV) impairs glucose metabolism and interferes with insulin-signaling pathways. About a third of HCV-infected patients develop Type 2 diabetes mellitus. Several evidences correlated direct-acting antiviral (DAA) based treatment of HCV infection with improved glycemic control. Patients & methods: Disturbance in glucose metabolism of two different HCV patients receiving DAA drugs was noticed. Results: We observed the first evidence of abrupt onset of diabetes and poor glycemic control in two different obese patients respectively, following successful treatment of HCV with sofosbuvir and ribavirin. Conclusion: This case is an evidence of potential glucose intolerance in HCV patients receiving DAA drugs. It further suggests the need for regular screening of patient during DAA therapy for early detection of diabetes or poor glycemic control.

KW - DAA

KW - diabetes

KW - interferon

KW - sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=85051985160&partnerID=8YFLogxK

U2 - 10.2217/fvl-2017-0147

DO - 10.2217/fvl-2017-0147

M3 - Article

AN - SCOPUS:85051985160

SN - 1746-0794

VL - 13

SP - 525

EP - 528

JO - Future Virology

JF - Future Virology

IS - 8

ER -

Poor Glycemic Control and Abrupt Onset of Diabetes in HCV Patients Receiving direct-acting Antiviral Drugs: Case Series

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this